Recursion Pharmaceuticals (RXRX) Beats Stock Market Upswing: What Investors Need to Know [Yahoo! Finance]
Recursion Pharmaceuticals, Inc. - Class A (RXRX)
Company Research
Source: Yahoo! Finance
This change outpaced the S&P 500's 0.22% gain on the day. Meanwhile, the Dow lost 0.33%, and the Nasdaq, a tech-heavy index, added 0.76%. Coming into today, shares of the biotechnology company had lost 8.13% in the past month. In that same time, the Medical sector lost 3.79%, while the S&P 500 gained 1.47%. The investment community will be closely monitoring the performance of Recursion Pharmaceuticals in its forthcoming earnings report. In that report, analysts expect Recursion Pharmaceuticals to post earnings of -$0.33 per share. This would mark year-over-year growth of 23.26%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $34.71 million, up 229.65% from the year-ago period. For the full year, the Zacks Consensus Estimates are projecting earnings of -$1.58 per share and revenue of $76.68 million, which would represent changes of 0% and +72.02%, respectively, from the prior year. It is also important to note the recent changes to analyst estim
Show less
Read more
Impact Snapshot
Event Time:
RXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RXRX alerts
High impacting Recursion Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RXRX
News
- Familial Adenomatous Polyposis Pipeline Landscape Report 2024 [Yahoo! Finance]Yahoo! Finance
- Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $11.00 price target on the stock.MarketBeat
- Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discoveryGlobeNewswire
- Recursion and Exscientia Shareholders Approve the Proposed CombinationGlobeNewswire
- Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model GardenGlobeNewswire
RXRX
Earnings
- 11/6/24 - Miss
RXRX
Sec Filings
- 11/21/24 - Form 144
- 11/20/24 - Form 8-K
- 11/20/24 - Form S-8
- RXRX's page on the SEC website